<DOC>
	<DOC>NCT01190657</DOC>
	<brief_summary>This is a self-controlled, open, multiple-center clinical trial.</brief_summary>
	<brief_title>Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Gastritis, Atrophic</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Geranylgeranylacetone</mesh_term>
	<criteria>Inclusion criteria 1. Age is over 18 years old , men or women 2. Erosive lesions or flat lesions with thin white coating in acute gastritis, acute stage of chronic gastritis with over three lesions (including three lesions) by endoscopy prior to study in 3 days or diagnosed by clinical symptoms and signs; 3. Signed the informed consent forms. Exclusion criteria 1. Patients without inclusion criteria 2. Patients with significant cardiovascular, pulmonary, hepatic, renal or hemopoietic system primary disease 3. Patients with other digestive diseases. 4. Patients with operation on stomach and duodenum. 5. Patients administered with nonsteroidal antiinflammatory drugs (NSAIDs) and corticosteroids 6. Patients with severity trauma, surgery, infection and shock. 7. Patients with any kind of tumor 8. Women either pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Teprenone</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>acute gastric lesion</keyword>
	<keyword>chronic gastritis</keyword>
</DOC>